Growth factor treatment of demyelinating disease: At last, a leap into the light

Richard M. Ransohoff, Charles L. Howe, Moses Rodriguez

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations

Abstract

Researchers seeking treatments for multiple sclerosis (MS) have long dreamed of using neurotrophic factors to enhance remyelination. Previous attempts to apply trophic support for oligodendrocytes in experimental demyelination uniformly produced complicated outcomes that reflected unexpected effects on immune or inflammatory responses and could be interpreted only with caution. Now, two recent publications have demonstrated convincingly that cytokines of the interleukin (IL)-6 superfamily can ameliorate experimental autoimmune encephalomyelitis and promote oligodendrocyte survival, without demonstrable effect on inflammation or immune responses.

Original languageEnglish (US)
Pages (from-to)512-516
Number of pages5
JournalTrends in Immunology
Volume23
Issue number11
DOIs
StatePublished - Nov 1 2002

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Growth factor treatment of demyelinating disease: At last, a leap into the light'. Together they form a unique fingerprint.

Cite this